IRLAB-A.ST

IRLAB Therapeutics AB (publ) [IRLAB-A.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IRLAB-A.ST Stock Summary

Top 10 Correlated Stocks

IRLAB-A.ST

In the News

IRLAB-A.ST Financial details

Company Rating
-
Market Cap
649.95M
Income
-177.89M
Revenue
5.68M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.69
Forward P/E
-
PEG
-0.48
P/S
24.79
P/B
3.2
P/C
-
P/FCF
-2.79
Quick Ratio
3.07
Current Ratio
3.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.43
EPS next Y
-
EPS next Q
-
EPS this Y
55.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.04%
Revenue last 5Y
193.66%
Revenue Q/Q
-
EPS Q/Q
-9.46%
-
-
-
-
SMA20
-4.95%
SMA50
-49.71%
SMA100
-46.23%
Inst Own
-
Inst Trans
-
ROA
-94%
ROE
-82%
ROC
-1.2%
Gross Margin
100%
Oper. Margin
-935%
Profit Margin
-925%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.58-20.2
52W High
-65.5%
52W Low
+38%
RSI
44.22
Rel Volume
0.3
Avg Volume
93.93K
Volume
28.24K
Perf Week
-0.72%
Perf Month
1.47%
Perf Quarter
-51.06%
Perf Half Y
-42.98%
-
-
-
-
Beta
0.456
-
-
Volatility
0.16%, 0.49%
Prev Close
4.7%
Price
6.9
Change
-1.43%

Something similar

Top by Market Cap
TL0.DE
M&M.NS
AMZ.DE
LLY.DE
APC.DE
Same Sector
002826.SZ
0JBU.L
PBYI
9987.T
0HTC.L
Top Correlated Stocks
BHL.L
Similar Market Cap
PWFL
FCU.TO
AWF
HXQ.TO
CLOU

Company Profile

Healthcare Biotechnology
  • Volume Average 93.93K
  • Market Capitalization 649.95M
  • Employee 31
  • CEO Mr. Gunnar Olsson
  • Headquarters Gothenburg,SE
  • IPO Date 2017-02-28
  • Website https://www.irlab.se

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.